PTGS2 and breast carcinoma: Elevation of COX-2 activity is reported in greater than 40% of all breast cancers [63] and preclinical data supporting the efficacy of NSAIDs in suppressing breast cancer has made COX-2 a logical target for breast cancer therapy and chemoprevention.